TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Purchased by Redwood Investments LLC

Redwood Investments LLC increased its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 0.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 94,554 shares of the biopharmaceutical company’s stock after purchasing an additional 886 shares during the quarter. Redwood Investments LLC owned about 0.06% of TG Therapeutics worth $2,846,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of TGTX. Bleakley Financial Group LLC acquired a new position in TG Therapeutics in the 4th quarter valued at approximately $245,000. Castellan Group bought a new stake in TG Therapeutics in the fourth quarter valued at about $8,539,000. Barclays PLC raised its stake in TG Therapeutics by 83.9% during the third quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company’s stock worth $8,117,000 after acquiring an additional 158,323 shares in the last quarter. Stratos Wealth Advisors LLC bought a new position in shares of TG Therapeutics in the fourth quarter valued at approximately $241,000. Finally, Strategic Financial Concepts LLC acquired a new position in TG Therapeutics during the 4th quarter worth about $1,404,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Stock Up 0.1%

TGTX stock opened at $33.40 on Thursday. The company has a market capitalization of $5.30 billion, a price-to-earnings ratio of -333.97 and a beta of 2.21. The stock has a fifty day moving average of $38.76 and a 200-day moving average of $33.78. TG Therapeutics, Inc. has a fifty-two week low of $15.16 and a fifty-two week high of $46.48. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.16). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $120.86 million for the quarter, compared to analysts’ expectations of $117.07 million. During the same quarter in the previous year, the business earned ($0.07) EPS. The company’s revenue for the quarter was up 90.4% on a year-over-year basis. As a group, equities research analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $40.80.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.